Frontotemporal dementia (FTD) is the second most common dementia syndrome in the elderly, and the most common for people under 65 years. There are currently no treatments. Loss-of-function mutations in the progranulin (PGRN, GRN) gene are an important cause of familial frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43)-positive inclusions (FTLD-TDP). The underlying mechanisms are largely unknown. PGRN in the brain is expressed in neurons and microglia. PGRN-deficient mouse models exhibit FTD-related behavioral deficits. One of the major pathologies is altered innate immune responses, in the forms of exacerbated microglial activation and elevated inflammatory responses associated with NF-kappaB hyperactivation. Our recent published study showed that selective reduction of microglial PGRN markedly enhances amyloid beta (Abeta) deposition, mostly likely via impairing phagocytosis, and exacerbates Abeta toxicity in Alzheimer's disease (AD) mouse models. In preliminary studies, we showed that selective deletion of PGRN in adult microglia recapitulates the FTD-like behavior alterations observed in Grn-/- mice. These studies strongly support the importance of microglial PGRN in balancing innate immune response and maintaining cognition in aging brain. Besides altered innate immune response, mice lacking PGRN also exhibit an early onset of lipofuscinosis reminiscent of that in lysosomal storage diseases. Based on these findings, we hypothesize that PGRN deficiency-induced endolysosmal dysfunction underlies aberrant microglial activation, leading to FTD- related dysfunction in circuits and cognition.
Three Aims are proposed to test this hypothesis.
Aim 1 is designed to determine decisively if GRN haploinsufficiency leads to endolysosomal dysfunction in human iPSC-derived neurons with GRN mutations and isogenic controls. Unbiased proteomic and pathway analyses will also be performed to probe the underlying mechanisms.
In Aim 2, we will test the hypothesis that PGRN deficiency-induced endolysosmal dysfunction underlies hyperactive NF-kappaB signaling, leading to microglial dysfunction. Specifically, we will determine if PGRN deficiency impairs endocytic turnover of innate response receptors and intracellular NF-kappaB signaling molecules. We will also determine if inactivating IkappaB kinase beta in PGRN deficient microglia restores microglial function.
In Aim 3, we will address how PGRN-deficient microglia lead to FTD-like cognitive deficits. Based on our preliminary studies, we will focus on medium spinal neurons (MSNs) in striatum, which exhibited elevated excitability in Grn-/- mice. Hyperactivity of MSNs has been associated with compulsive behaviors often observed in FTD patients. We will determine if PGRN-deficient microglia are sufficient to induce alterations in striatal circuits, and if selectiv inactivation of NF-kappaB rescues cognitive and circuit deficits induced by PGRN-deficient microglia. Completion of the aims will yield fundamental insights into the role of innate immunity in FTD-related behavioral disturbance and circuit dysfunction, which could lay the foundation for development of disease-modifying therapies for FTD patients.

Public Health Relevance

This project aims at investigating mechanisms underlying frontotemporal dementia associated with progranulin deficiency. This study may provide new therapeutic avenue for treating this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG051390-04
Application #
9484203
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Opanashuk, Lisa A
Project Start
2015-09-01
Project End
2020-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Min, Sang-Won; Sohn, Peter Dongmin; Li, Yaqiao et al. (2018) SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. J Neurosci 38:3680-3688
Sayed, Faten A; Telpoukhovskaia, Maria; Kodama, Lay et al. (2018) Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci U S A 115:10172-10177
Martinez-Losa, Magdalena; Tracy, Tara E; Ma, Keran et al. (2018) Nav1.1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer's Disease. Neuron 98:75-89.e5
Wang, Chao; Telpoukhovskaia, Maria A; Bahr, Ben A et al. (2018) Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Curr Opin Neurobiol 48:52-58
Ward, Michael E; Chen, Robert; Huang, Hsin-Yi et al. (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med 9:
Krabbe, Grietje; Minami, S Sakura; Etchegaray, Jon I et al. (2017) Microglial NF?B-TNF? hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. Proc Natl Acad Sci U S A 114:5029-5034
Wang, Chao; Ward, Michael E; Chen, Robert et al. (2017) Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening. Stem Cell Reports 9:1221-1233
Tracy, Tara E; Sohn, Peter Dongmin; Minami, S Sakura et al. (2016) Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron 90:245-60
Minami, S Sakura; Shen, Vivian; Le, David et al. (2015) Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with ?7 nicotinic acetylcholine receptor agonists. Biochem Pharmacol 97:454-462